Welcome to the e-CCO Library!

P377: Complications related to varicella zoster virus infection in patients with inflammatory bowel disease in the pre-JAK inhibitors era: A prospective study
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. de Francisco1,2*, A. Castaño1, P. Flórez-Díez1, S. Martínez-González1, I. Pérez-Martínez1, N. Rodríguez-Ferreiro1, V. Jiménez-Beltrán1, A. Suárez1,2, S. Riestra1,2

Created: Thursday, 21 February 2019, 9:14 AM
P377: Evaluation of the pharmacokinetic profiles of SB5 and reference adalimumab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Shin D.1, Kang J.W.2, Park S.2, Cheong S.Y.1, Hong E.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P377: Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study
Year: 2022
Source: ECCO'22
Authors: Allez, M.(1);Lewis, J.D.(2);Hanauer, S.B.(3);Danese, S.(4);Irving, P.M.(5,6);Gasink, C.(7);Hoops, T.(8);Izanec, J.L.(7);Ma, T.(7);Loftus- Jr., E.V.(9);Scherl, E.J.(10);Panaccione, R.(11);Sandborn, W.J.(12);Sands, B.E.(13);
Created: Friday, 11 February 2022, 3:52 PM
P377: Inadequate response with advanced therapies in real-world patients with Ulcerative Colitis – Results of a German claims database study
Year: 2021
Source: ECCO'21 Virtual
Authors: Bokemeyer, B.(1);Picker, N.(2);Wilke, T.(3);Rosin, L.(4);Patel, H.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P377: Serum adalimumab trough levels required for mucosal healing during maintenance therapy in patients with Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

H. Imaeda*, Y. Morita, T. Fujimoto, K. Takahashi, M. Shioya, A. Nishida, O. Inatomi, S. Bamba, M. Sasaki, T. Tsujikawa, M. Sugimoto, A. Andoh

Created: Friday, 22 February 2019, 9:49 AM
P378 Mucosal healing is achieved in most of the inflammatory bowel disease patients in clinical remission with vedolizumab: a real-life single-centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.I. Calvo Moya1, I. Omella Usieto1, M.I. Vera Mendoza1, V. Matallana Royo1, I. Gonzalez Partida1, M. Manso Manrique2, B. Menchén Viso2, R. De Lucas Téllez de Meneses1, M. González Rodriguez1, P. Bella del Castillo1, Y. González Lama1

Created: Thursday, 30 January 2020, 10:12 AM
P378: Changes in Simplified Endoscopic Score for Crohn’s disease (SES-CD) during a 16-week induction treatment with upadacitinib: analysis of the randomised controlled CELEST study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Feagan*1, W. Sandborn2, S. Schreiber3, B. Huang4, G. Alperovich4, A. Pangan4, A. Lacerda4, G. D’Haens5

Created: Friday, 22 February 2019, 9:41 AM
P378: Immunisation practices for hepatitis B and response to vaccination in Greek patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Kalogera1*, S. Siakavellas1, E. Zambeli2, E. Tsironi3, M. Tzouvala4, D. Moschovis4, A. Kostas1, G. Axiaris2, E. Kourkoutas2, K. Filippakou3, J. Vlachogiannakos1, S. Michopoulos2, G. Papatheodoridis1, G. Bamias5

Created: Thursday, 21 February 2019, 9:14 AM
P378: Oxidative status and antioxidant capacity in children and adults with IBD: preliminary results of the OxIBDiet trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Gatti, S.(1);Cianfruglia, L.(2);Galeazzi, T.(1);Palpacelli, A.(1);Quattrini, S.(1);Quatraccioni, C.(3);Catassi, G.(1);Monachesi, C.(1);Di Sario, A.(3);Armeni, T.(2);Catassi, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P378: Pharmacokinetics of Vedolizumab and Ustekinumab in pregnant women with Inflammatory Bowel Disease and their infants exposed in-utero
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Prentice, R.(1)*;Flanagan, E.(2);Wright, E.K.(2);Gibson, P.R.(3);Rosella, S.(3);Rosella, O.(3);Goldberg, R.(1);Prideaux, L.(4);Kiburg, K.(5);Ross, A.L.(2);Burns, M.(1);Bell, S.J.(4);
Created: Friday, 14 July 2023, 11:05 AM
P378: Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE Open
Year: 2022
Source: ECCO'22
Authors: Allegretti, J.R.(1);Gecse, K.B.(2);Chiorean, M.V.(3);Argollo, M.(4);Guo, X.(5);Lawendy, N.(5);Su, C.(5);Mundayat, R.(6);Paulissen, J.(6);Salese, L.(5);Irving, P.M.(7);
Created: Friday, 11 February 2022, 3:52 PM
P378: Renal AA amyloidosis associated with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bibani N., Gharbi O., Trad D., Sabbah M., Ouakaa A., Gargouri D., Elloumi H., Kharrat J.

Created: Wednesday, 20 February 2019, 10:36 AM
P378: The outcomes of a clinical care pathway for inflammatory bowel disease surgery
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Platt*1, A. Lightner2, R. Jacobs1, D. Sagar1, W. van Deen1, T. Hommes1, S. Reardon3, J. Sack3, D. Hommes1

Created: Friday, 22 February 2019, 9:49 AM
P379 Surveillance with chromoendoscopy to detect new dysplasia in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Villar Lucas, R. Quiñones Castro, L. Vaquero Ayala, P. Suárez Álvarez, M.J. Fernández Gundin, M. Sierra Ausín

Created: Thursday, 30 January 2020, 10:12 AM
P379: Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naïve patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Latremouille-Viau1, R. Burne1, S. Shi1, S. Adsul2, H. Patel*2

Created: Friday, 22 February 2019, 9:41 AM
P379: Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn's disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Danese, S.(2,3);Cohen, B.L.(4);Magro, F.(5);Chen, Y.(6);Ha, C.(7);Dubcenco, E.(8);Lacerda, A.P.(8);Marced, E.(8);Oomen, J.(8);Garrison, A.(8);Peyrin-Biroulet, L.(9);
Created: Friday, 14 July 2023, 11:05 AM
P379: Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. S. Prüß*, A. Farmer, B. Siegmund

Created: Friday, 22 February 2019, 9:49 AM
P379: Infliximab or adalimumab: Which should be used first for Crohn’s disease? A multicentre retrospective observational study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Takahashi1*, T. Inokuchi2, S. Hiraoka2, T. Toyokawa3, S. Takagi4, K. Takemoto5, J. Miyaike6, T. Fujimoto7, R. Higashi8, H. Yasuhara9, T. Nawa10, S. Suzuki11, J. Kato12, H. Okada2

Created: Thursday, 21 February 2019, 9:14 AM
P379: Is febuxostat the solution for patients who develop side effects to low dose azathioprine and allopurinol co-therapy?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Johnson H., Wade K., Hovell C., Weaver S., McLaughlin S.

Created: Wednesday, 20 February 2019, 10:36 AM
P379: Trends in Colectomy Rates and Biologic use over a 30-year period: What has changed?
Year: 2022
Source: ECCO'22
Authors: Doherty, J.(1);Stack, R.(1);Fennessy, A.(1);Cullen, G.(1);Mulcahy, H.(1);Sheridan, J.(1);Kevans, D.(1);Doherty, G.(1);
Created: Friday, 11 February 2022, 3:52 PM